Liglimet XR 5 mg+1000 mg (Tablet (Extended Release))
Unit Price: ৳ 20.00 (5 x 4: ৳ 400.00)
Strip Price: ৳ 80.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Linagliptin metformin hydrochloride |
| Company | Square pharmaceuticals plc |
| Also available as |
Therapeutic Class
- Combination Oral hypoglycemic preparations
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pharmacology
- Inhibitor of DPP-4 (dipeptidyl peptidase-4)
- Increatin hormone stimulator
- Glucose-dependent insulinotropic polypeptide stimulator
- Insulin release stimulator
- Glucagon secretion reducer
- Oral antihyperglycemic drug
- Basal and postprandial plasma glucose reducer
- Hepatic glucose production reducer
- Intestinal glucose absorption reducer
- Insulin sensitivity enhancer
- Peripheral glucose uptake and utilization enhancer
Dosage & Administration
- Individualized dosage based on effectiveness and tolerability
- Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals
- Gradual dose escalation to reduce gastrointestinal side effects
- Recommended starting dose of 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily for patients not treated with Metformin Hydrochloride
- Recommended starting dose of 2.5 mg Linagliptin and current dose of Metformin Hydrochloride for patients already treated with Metformin Hydrochloride
- Switching to combination containing same doses of each component
- Individualized dosage for extended-release tablet not exceeding the maximum recommended total daily dose
- Various initial dosages and switching guidelines for different patient scenarios
- Specific dosing instructions for extended-release tablet
Interaction
- Potential interaction with cationic drugs
- Careful patient monitoring and dose adjustment recommendation for cationic medications
- Caution with carbonic anhydrase inhibitors
- Potential decrease in Linagliptin exposure with rifampin use
- Recommendation for alternative treatments when concomitant treatment with strong P-gp or CYP 3A4 inducer is necessary
- Drugs affecting glycemic control and their impact on glycemic control
- Recommendation for close observation during drug administration and withdrawal
Contraindications
- Contraindicated in patients with renal impairment
- Contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis)
- Contraindicated in hypersensitivity to Linagliptin or Metformin Hydrochloride
Side Effects
- Common side effects include nasopharyngitis and diarrhea
- Increased risk of hypoglycemia in patients treated with Liglimet XR and sulfonylureas
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Caution advised during pregnancy and lactation
Precautions & Warnings
- Discontinuation and supportive therapy recommendation in lactic acidosis cases
- Prompt discontinuation in case of suspected pancreatitis
- Temporary discontinuation in certain medical procedures
- Hematologic parameters monitoring for Metformin effect on Vitamin B12 levels
- Symptoms of lactic acidosis and pancreatitis
- Instructions on alcohol, other medicines, counseling, travel, and emergency preparedness
- Hypoglycemia risk factors and symptoms
Overdose Effects
- Usual supportive measures recommendation in event of overdose
- Hemodialysis or peritoneal dialysis unlikely to remove Linagliptin
- Metformin Hydrochloride dialyzable
- No dose-related clinical adverse drug reactions observed with Linagliptin overdose
- Reported hypoglycemia and lactic acidosis cases with Metformin Hydrochloride overdose
Storage Conditions
- Cool & dry place below 30°C
- Protected from light & moisture
- Keep out of the reach of children